238 related articles for article (PubMed ID: 2574209)
1. [Clinical usefulness of the combination assay of CA 125, SLX, and CA 72-4 in patients with ovarian cancer].
Kobayashi H; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov; 41(11):1731-5. PubMed ID: 2574209
[TBL] [Abstract][Full Text] [Related]
2. [Diagnosis and follow-up of ovarian cancer by a combination assay of serum sialyl SSEA-1 antigen and CA125 levels].
Iwanari O; Miyako J; Date Y; Moriyama M; Yoshino N; Kijima S; Nakayama S; Ryuhkoh K; Moriyama M; Hata T
Nihon Gan Chiryo Gakkai Shi; 1989 Jun; 24(6):1256-60. PubMed ID: 2571650
[TBL] [Abstract][Full Text] [Related]
3. [Diagnostic value of serological tumor marker tests in patients with ovarian cancer].
Kobayashi H; Sumimoto K; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Oct; 41(10):1501-6. PubMed ID: 2573640
[TBL] [Abstract][Full Text] [Related]
4. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for sialyl TN antigen: (2). Evaluation of clinical significance. STN Study Group].
Imura H; Mori T; Ohkura H; Ishii M; Ariyoshi H; Endo J; Kitao M; Takeda I; Kobayashi H; Inoue M
Gan To Kagaku Ryoho; 1989 Sep; 16(9):3221-30. PubMed ID: 2571323
[TBL] [Abstract][Full Text] [Related]
5. Differential diagnosis of ovarian cancer, benign ovarian tumor and endometriosis by a combination assay of serum sialyl SSEA-1 antigen and CA125 levels.
Iwanari O; Miyako J; Date Y; Nakayama S; Kijima S; Moriyama M; Takahashi K; Yoshino N; Karino K; Endoh J
Gynecol Obstet Invest; 1990; 29(1):71-4. PubMed ID: 1972127
[TBL] [Abstract][Full Text] [Related]
6. [The clinical usefulness of serum CA72-4 analysis in patients with ovarian cancer].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):585-9. PubMed ID: 2754289
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer.
Kobayashi H; Terao T; Kawashima Y
J Clin Oncol; 1991 Jun; 9(6):983-7. PubMed ID: 1851822
[TBL] [Abstract][Full Text] [Related]
8. Clinical use of CA 125 and its combination assay with other tumor marker in patients with ovarian carcinoma.
Negishi Y; Furukawa T; Oka T; Sakamoto M; Hirata T; Okabe K; Matayoshi K; Akiya K; Soma H
Gynecol Obstet Invest; 1987; 23(3):200-7. PubMed ID: 3474196
[TBL] [Abstract][Full Text] [Related]
9. [The clinical significance of serum sialyl SSEA-1 antigen in obstetrical and gynecological patients].
Tanaka T; Iwasaka T; Hayashi Y; Hachisuga T; Yokoyama M; Ohkuma Y; Matsuo N; Fukuda K; Sugimori H
Nihon Gan Chiryo Gakkai Shi; 1990 Jun; 25(6):1157-61. PubMed ID: 1975831
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluations of the tumor marker sialyl SSEA-1 antigen for clinical gynecological disease.
Iwanari O; Miyako J; Date Y; Nakayama S; Kijima S; Moriyama M; Karino K; Endoh J; Kitao M
Gynecol Obstet Invest; 1990; 29(3):214-8. PubMed ID: 1972688
[TBL] [Abstract][Full Text] [Related]
11. Comparative measurement of ovarian carcinoma antigen and carcinoembryonic antigen in the serum of ovarian cancer.
Yuan CC; Ng HT; Tsai LC; Jeng FS; Yeh SH; Tsai YC
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1987 Aug; 20(3):190-7. PubMed ID: 3480793
[TBL] [Abstract][Full Text] [Related]
12. Serum and tissue measurements of CA72-4 in ovarian cancer patients.
Negishi Y; Iwabuchi H; Sakunaga H; Sakamoto M; Okabe K; Sato H; Asano G
Gynecol Oncol; 1993 Feb; 48(2):148-54. PubMed ID: 8381375
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of sialyl SSEA-1 antigen in patients with ovarian cancer.
Suzuki M; Ohwada M; Tamada T
Gynecol Oncol; 1990 Mar; 36(3):371-5. PubMed ID: 1969379
[TBL] [Abstract][Full Text] [Related]
14. [Studies on CA 125, CA 19-9, TPA and IAP as tumor markers in patients with ovarian cancer].
Negishi Y; Furuno K; Sano Y; Hirata T; Utsunomiya A; Nakajima H; Okabe K; Shimizu K; Akiya K; Fujiwara Y
Gan No Rinsho; 1985 May; 31(6 Suppl):655-63. PubMed ID: 2993692
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of CA 125 assay system and its diagnostic significance in gynecologic tumors].
Shimizu Y; Akagaki E; Hirota K; Kono M; Miura S; Okudaira Y
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec; 37(12):2813-20. PubMed ID: 3866801
[TBL] [Abstract][Full Text] [Related]
16. Relationship of serum CA125 and lipid-associated sialic acid tumor-associated antigen levels to the disease status of patients with gynecologic malignancies.
Stratton JA; Rettenmaier MA; Phillips HB; Herabutya S; DiSaia PJ
Obstet Gynecol; 1988 Jan; 71(1):20-6. PubMed ID: 2827081
[TBL] [Abstract][Full Text] [Related]
17. The clinical significance of pre-operative serum CA 125 in ovarian cancer.
Cruickshank DJ; Fullerton WT; Klopper A
Br J Obstet Gynaecol; 1987 Jul; 94(7):692-5. PubMed ID: 2441738
[TBL] [Abstract][Full Text] [Related]
18. [Serum level of the tumor marker CA 125 in ovarian pathology].
Bagni B; Pansini FS; Feggi LM; Prandini N; Mollica G
Radiol Med; 1987 Nov; 74(5):448-50. PubMed ID: 3479814
[TBL] [Abstract][Full Text] [Related]
19. Role of Ca 125 as tumor marker in ovarian carcinoma.
Krebs HB; Goplerud DR; Kilpatrick SJ; Myers MB; Hunt A
Obstet Gynecol; 1986 Apr; 67(4):473-7. PubMed ID: 3008052
[TBL] [Abstract][Full Text] [Related]
20. [Serodiagnostic tests by factor analysis and stepwise discriminating analysis with tumor markers for the detection of ovarian cancer].
Kobayashi H; Sumimoto K; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1903-10. PubMed ID: 2480396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]